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Regulation of smooth muscle myosin phosphatase
(SMPP-1M) is thought to be a primary mechanism for
explaining Ca2 sensitization/desensitization in smooth
muscle. Ca2 sensitization induced by activation of G
protein-coupled receptors acting through RhoA in-
volves phosphorylation of Thr-696 (of the human iso-
form) of the myosin targeting subunit (MYPT1) of
SMPP-1M inhibiting activity. In contrast, agonists that
elevate intracellular cGMP and cAMP promote Ca2 de-
sensitization in smooth muscle through apparent acti-
vation of SMPP-1M. We show that cGMP-dependent pro-
tein kinase (PKG)/cAMP-dependent protein kinase
(PKA) efficiently phosphorylates MYPT1 in vitro at Ser-
692, Ser-695, and Ser-852 (numbering for human iso-
form). Although phosphorylation of MYPT1 by PKA/PKG
has no direct effect on SMPP-1M activity, a primary site
of phosphorylation is Ser-695, which is immediately ad-
jacent to the inactivating Thr-696. In vitro, phosphoryl-
ation of Ser-695 by PKA/PKG appeared to prevent phos-
phorylation of Thr-696 by MYPT1K. In ileum smooth
muscle, Ser-695 showed a 3-fold increase in phosphoryl-
ation in response to 8-bromo-cGMP. Addition of consti-
tutively active recombinant MYPT1K to permeabilized
smooth muscles caused phosphorylation of Thr-696 and
Ca2 sensitization; however, this phosphorylation was
blocked by preincubation with 8-bromo-cGMP. These
findings suggest a mechanism of Ca2 desensitization in
smooth muscle that involves mutual exclusion of phos-
phorylation, whereby phosphorylation of Ser-695 pre-
vents phosphorylation of Thr-696 and therefore inhibi-
tion of SMPP-1M.
Contraction and relaxation of smooth muscle are primarily
determined by the level of phosphorylation of the myosin light
chain (MLC-20).1 To initiate contraction, an action potential or
binding of a contractile agonist causes an increase in intracel-
lular Ca2, which activates myosin light chain kinase (MLCK),
a Ca2/calmodulin-dependent enzyme. MLCK phosphorylates
MLC-20 on serine 19, resulting in contraction of smooth muscle
through increases in myosin ATPase activity and cross-bridge
cycling (1, 2). Smooth muscle myosin phosphatase (SMPP-1M)
dephosphorylates MLC-20 resulting in relaxation of smooth
muscle. Contraction can also occur in response to certain sig-
nals in the absence of changes in intracellular Ca2, a phenom-
enon called Ca2 sensitization. Inhibition of SMPP-1M activity
is a primary mechanism of Ca2 sensitization (3–7). One hy-
pothesis is that SMPP-1M activity is inhibited by phosphoryl-
ation of the targeting subunit, MYPT1, at Thr-696 (of the
human isoform). Several kinases have been shown to phospho-
rylate this site including Rho kinase (ROCK) (6), MYPT1-
associated kinase (MYPT1K or ZIPK) (5, 8), myotonic dystro-
phy kinase (9), and integrin-linked kinase (9, 10).
Relaxation of smooth muscle is achieved by either removal of
the contractile agonist (passive relaxation) or through agonists
that activate guanylyl or adenylyl cyclase and stimulate the
production of cyclic nucleotides, cGMP or cAMP, thus activat-
ing their targets, cGMP-dependent protein kinase (PKG) and
cAMP-dependent protein kinase (PKA) (2, 3). These kinases
lower intracellular Ca2 through multiple mechanisms, but
they also raise the Ca2 threshold for contraction, thus causing
Ca2 desensitization (3, 11). This is illustrated by the observa-
tion that GTPS and carbachol-contracted smooth muscle relax
in response to 8-bromo-cGMP at constant Ca2 (12, 13). These
findings suggest the mechanism of Ca2 desensitization in-
volves direct activation of SMPP-1M by the cyclic nucleotide-
dependent kinases PKA and PKG. Indeed, several studies in
permeabilized muscle have suggested that cGMP/PKG stimu-
lates endogenous SMPP-1M activity; however, none have
shown a direct activation (12–14). In vitro the MYPT1 phos-
phorylation data suggest that multiple serine residues are
phosphorylated by PKA/PKG; specifically Ser-849 (M133 iso-
form) was suggested because it is in a PKG phosphorylation
consensus sequence, and the C-terminal portion of the protein
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was found to be phosphorylated (15). In smooth muscle, the
presence of the leucine zipper domain of both PKG and MYPT1
has been shown to be essential for the protein kinase to medi-
ate relaxation as determined by MLC-20 phosphorylation, al-
though the binding of PKG-1 to MYPT1 does not absolutely
require the leucine zipper domain (16–18). Pretreatment of
vascular smooth muscle cells with 8-bromo-cGMP before treat-
ment with angiotensin II reduces MYPT1 Thr-696 phosphoryl-
ation (4). Activation of SMPP-1M was suspected, but activity
was measured indirectly by assessing MLC dephosphorylation.
The study suggested that phosphorylation by PKA/PKG may
inhibit Thr-696 phosphorylation and thus a decrease in the
level of inhibition of SMPP-1M rather than an activation.
To investigate the mechanisms by which PKA/PKG might
bring about Ca2 desensitization through direct interactions
with SMPP-1M, we first identified all the major sites phospho-
rylated by these kinases on MYPT1 in vitro. We identified three
serine residues on MYPT1 that are phosphorylated by PKA/
PKG (Ser-692, Ser-695, and Ser-852, human isoform number-
ing), and we showed specifically that phosphorylation of Ser-
695 precludes phosphorylation at the inactivating site Thr-696
by MYPT1K and ROCK in vitro. The reverse situation also
occurred. Treatment of permeabilized ileal smooth muscles
with 8-bromo-cGMP induced phosphorylation of Ser-695 and
greatly attenuated the Ca2-sensitizing effects of exogenous
MYPT1K. These findings suggest that one way cyclic nucleo-
tides mediate their Ca2-desensitizing effects in smooth mus-
cle is by blocking the inhibitory phosphorylation mechanism for
SMPP-1M.
EXPERIMENTAL PROCEDURES
Materials—Affinity-purified MYPT1 antibody was made by Quality
Control Biochemicals (Hopkington, MA) in rabbits by using a recombi-
nant N-terminal fragment of rat MYPT1 as the antigen. Affinity-puri-
fied MYPT1pS695 antibody (Invitrogen) was produced in rabbits by using
the peptide KLHRQSRRpSTQGVT (where pS is phosphoserine). This
peptide was synthesized by Biomolecules Midwest (St. Louis, MO).
Affinity-purified pMYPT1T696 antibody and ROCK (an N-terminal frag-
ment) were from Upstate Group, Inc. (Charlottesville, VA). The
MYPT1K substrate peptide from MYPT1 (689RQSRRSTQGVTL700) and
the serine to alanine mutant peptide (689RQARRSTQGVTL700) (chicken
M133 numbering) were synthesized by Biomolecules Midwest. cGMP-
dependent protein kinase and the catalytic subunit of PKA were from
Calbiochem, and 8-bromo-cGMP was from Sigma. Native PP-1c from
rabbit skeletal muscle was a gift from Shirish Shenolikar (Durham,
NC), and 32P-labeled myosin from pig bladder (19) or 32P-labeled giz-
zard MLC-20 (9) was prepared as described.
Expression and Purification of Recombinant Proteins—Recombinant
MYPT1 kinase (rMYPT1K) encoding the N-terminal portion of the
protein was produced as described from I.M.A.G.E. clone A1660136 (8).
The cDNA clone was inserted in-frame into pGEX-6-P-1 in the NotI/
BamHI sites (Amersham Biosciences). Escherichia coli cells were grown
in LB broth in 50 g/ml ampicillin overnight at 37 °C. Cells were
incubated in 300 M isopropyl-1-thio--D-galactopyranoside for 2 h to
induce protein expression, and GST-MYPT1K was isolated by using
glutathione-Sepharose. The GST moiety was cleaved by an overnight
digestion with Precission Protease® according to the manufacturer’s
protocol (Amersham Biosciences). A hexahistidine-tagged C-terminal
fragment of MYPT1 (sequence 514–963 of the M130 chicken isoform;
termed C130), full-length chicken GST-MYPT1 (M133), and rat GST-
MYPT1 (M110) were expressed and purified as described (6, 20, 21).
Muscle Tension Measurement—For in situ contractile experiments,
adult male New Zealand White rabbits were anesthetized with halo-
thane and exsanguinated according to approved animal protocols. Il-
eum smooth muscle was removed, and strips of muscle (5 mm  200
m) were cut and the ends tied with silk suture. The muscle strips were
then mounted in 140-l ‘‘bubble chambers.’’ One end of each strip was
attached to a force transducer (SensorOne AE801, Sausalito, CA), and
tension was set to 1.3 times resting length. The strips were permeabi-
lized with -escin (50 M) for 30 min at room temperature in Ca2-free
solution containing 1 mM EGTA (G1). Muscles were treated with the
Ca2 ionophore A23187 (10 M) for 10 min to deplete intracellular Ca2
stores. After extensive washing in G1, muscles were stimulated with 10
mM Ca2 solution (CaG) for 5 min and then washed extensively and
placed in G1. Either vehicle (water) or 8-bromo-cGMP (100 M) was
administered for 5 min, followed by rMYPT1K (10 M) for 10 min. The
strips were washed extensively again and then contracted in CaG.
Force and rate of contraction were measured as a percent of the max-
imum contraction in CaG.
Western Blot Analysis of Smooth Muscle Tissue—Rabbit ileum was
collected as described above, and squares (5  5 mm) were mounted in
a silicone bottom dish. The muscles were permeabilized and washed as
described above. To test the phosphorylation of Ser-695, the ileum was
treated with vehicle (water) or 8-bromo-cGMP (100 M) for 10 min and
then flash-frozen in liquid N2-cooled Freon. To test the level of Thr-696
phosphorylation after pretreatment with 8-bromo-cGMP, muscles were
treated with vehicle or 8-bromo-cGMP (100 M) for 5 min, followed by
10 M rMYPT1K for 10 min, and then flash-frozen in liquid N2-cooled
Freon. The frozen squares were stored in 10% trichloroacetic acid in
acetone, thawed, washed in acetone, and then homogenized in buffer
containing 600 mM NaCl, 25 mM Tris-HCl, pH 7.0, 0.5% Triton X-100, 1
g/ml leupeptin, 1 g/ml aprotinin, 1 mM dithiothreitol, 2 mM EGTA,
and 1 M microcystin-LR. Homogenates were resolved on a 10% SDS-
polyacrylamide gel and transferred to polyvinylidene difluoride mem-
branes. Nonspecific binding sites were blocked with 5% nonfat dry milk
in Tris-buffered saline containing 0.5% Tween 20. Blots were incubated
overnight with primary antibody directed against phospho-Ser-695 of
MYPT1 (1:1,000) or with primary polyclonal antibody directed against
nonphosphorylated MYPT1 (1:2000). The blots were washed and incu-
bated with horseradish peroxidase-conjugated rabbit secondary anti-
body (1:2000) for 1 h and developed with enhanced chemiluminescence
(Amersham Biosciences). Bands were quantitated by densitometry, and
the relative phosphorylation was determined as a function of the density
of total MYPT1. Equal protein loading was determined by Amido Black
staining of the polyvinylidene difluoride membranes after blotting.
In Vitro Phosphorylation, Kinase, and Phosphatase Assays—All
phosphorylation reactions for site analysis were carried out by using
100 g of MYPT1 (c130), 5 g of PKAc or PKG, 50 mM HEPES, pH 7.2,
1 mM MgCl2, and 0.2 mM [-
32P]ATP (2,500 cpm/nmol). For stoichiom-
etry reactions, 2 M GST-MYPT1 (or C130) was phosphorylated by PKA
(1 g/ml), ROCK (0.4 units/ml), or rMYPT1K (44 g/ml) in the presence
of 50 mM HEPES, pH 7.2, 1 mM MgCl2, and 0.2 mM [-
32P]ATP (2500
cpm/nmol). For phosphatase assays, GST-MYPT1 (M110) was mixed
with an equimolar amount of native rabbit PP1C. Smooth muscle my-
osin phosphatase assays were performed by using 32P-labeled myosin as
described previously (19). Kinase assays with the substrate peptide
were carried out at 25 °C in 50-l reactions with 50 mM HEPES, pH 7.2,
1 mM MgCl2, 0.2 mM [-
32P]ATP (2500 cpm/nmol), 100 M MYPT1
Ser-691 to Ala substrate peptide, and 0.3 M rMYPT1K. Reactions were
terminated by spotting on P81 paper after a time course. P81 papers
were washed three times in 20 mM H3PO4, placed in 1.5-ml Eppendorf
tubes, and Cerenkov counted. Kinase assays for sequential phosphoryl-
ation of MYPT1 by PKA, ROCK, or rMYPT1K were carried out as
described previously (9) by using GST-MYPT1 (2 M), PKA (1 g/ml), or
ROCK (0.4 units/ml) or rMYPT1K (44 g/ml). Phosphorylation was
initiated with one kinase, and then part of the reaction mixture was
removed and continued with a second kinase. Incorporation of 32P
was estimated by Cerenkov counting as above. GST-MYPT1 (2 M) was
thiophosphorylated by PKA (1 g/ml) for 150 min with 0.5 mM ATPS
(other conditions as in Ref. 9) and dialyzed against 20 mM Tris-HCl, pH
7.5, 85 mM KCl, 5 mM MgCl2, 10 mM EGTA, and 4 mM dithiothreitol.
The thiophosphorylated GST-MYPT1 was then subjected to phospho-
rylation with ROCK (0.4 units/ml) in 0.2 mM [-32P]ATP. A non-thio-
phosphorylated GST-MYPT1 was phosphorylated by ROCK, as a con-
trol. Aliquots of each reaction were removed at intervals to measure
phosphate incorporation and also for use in Western blots with the
MYPT1pT696 antibody. At the end of the reaction period, the two sam-
ples were assayed for inhibition of native PP1c (0.5 nM) by using
32P-MLC-20 (5 M) as substrate (9).
Phosphorylation Site Analysis—Phosphorylated MYPT1 was di-
gested either with endoprotease Lys-C (6 g/mg) or V8 endoprotease E
(V8 protease) (6 g/mg) overnight, and phosphopeptides were separated
by reverse phase HPLC. Radioactive peptides were collected and cross-
linked to Immobilon P filters (Applied Biosystems) as described (22).
The filters were placed in an ABI 474cLC Edman sequenator configured
to collect the phenylthiohydantoin-derivatives immediately following
cleavage of the N-terminal amino acid with trifluoroacetic acid. The
amount of radioactivity released after each Edman cycle was deter-
mined by Cerenkov counting. The cleaved radioactive peptide (CRP)
algorithm (fasta.bioch.virginia.edu/crp/) using lysine as the cleavage
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point was used to identify all possible serine/threonine residues in the
MYPT1K sequence that corresponded to release of radioactivity during
Edman sequencing. To precisely identify each site, the experiment was
repeated following digestion with V8 protease. CRP analysis was re-
peated using glutamic acid as the cleavage site. Cross-referencing re-
lease of radioactivity after cleavage at lysine with glutamic acid unam-
biguously identified three PKA/PKG phosphorylation sites on MYPT1.
Statistical Analysis—All results are reported as mean  S.E. A
Student’s unpaired t test was used to determine the statistical signifi-
cance of Ser-695 and Thr-696 phosphorylation in smooth muscles and of
changes in smooth muscle contraction. p  0.05 was considered
significant.
RESULTS
Treatment of Smooth Muscle Strips with 8-Bromo-cGMP At-
tenuates the Ca2-sensitizing Effect of MYPT1K—Treatment of
isolated smooth muscles with 8-bromo-cGMP is known to bring
about relaxation in a Ca2-independent manner (13). The pri-
mary target for cGMP is PKG, yet the mechanisms by which
the protein kinase brings about Ca2 desensitization are un-
clear. We sought to determine whether phosphorylation of
MYPT1 by PKG reduced the level of Ca2 sensitization induced
by MYPT1K. Addition of constitutively active rMYPT1K to
permeabilized smooth muscle is known to phosphorylate
MYPT1 (at Thr-696), inhibit endogenous SMPP-1M activity,
and produce a marked Ca2 sensitization (5, 8). The effect of
pretreatment with 8-bromo-cGMP on contraction elicited by
rMYPT1K was analyzed. Treatment of permeabilized muscle
with rMYPT1K elicited a contraction that was 41.8  0.9% of
the maximum Ca2 (CaG) contraction (Fig. 1, A and C). Pre-
treatment with 100 M 8-bromo-cGMP before rMYPT1K ad-
ministration significantly reduced the contraction to 19 
6.54% (n  5, p  0.04) of the maximum Ca2 contraction (Fig.
1, B and C). The findings suggest a possible mechanism of Ca2
desensitization, whereby phosphorylation of SMPP-1M or
other proteins attenuates the Ca2-sensitizing actions of
MYPT1K in smooth muscle.
Characterization of the Site Phosphorylated on rMYPT1 by
PKA/PKG in Vitro—To investigate the hypothesis that PKG/
PKA may bring about their Ca2-desensitizing effects through
phosphorylation of MYPT1, we identified the phosphorylation
sites by using a recombinant fragment of MYPT1 (C130). Fig.
2A (inset) shows that PKG efficiently phosphorylated C130 to
3.5 mol of phosphate/mol of C130. Phosphoamino acid anal-
ysis revealed that the fully phosphorylated protein contained
phosphoserine. Some phosphothreonine was seen if the in vitro
phosphorylation reaction was carried out to 2.5 h. To identify
the phosphorylation sites, C130 was phosphorylated with PKA
or PKG in the presence of [-32P]ATP, and the phosphorylated
protein was digested with endolysine protease C. The digest
was separated by reverse phase HPLC, and phosphopeptides
were identified in column fractions by Cerenkov counting (Fig.
2A). Three peaks of radioactivity were identified and cross-
linked to Immobilon P filters (Applied Biosystems, Inc.) as
described (22). The Immobilon filters were placed in an auto-
mated Edman sequenator, and after each Edman cycle, the
amount of radioactivity released from each cross-linked peptide
was determined by Cerenkov counting (Fig. 2, B–D). Peak 1
yielded radioactivity at cycle 3; peak 2 at cycles 4, 9, and 12;
and peak 3 at cycles 4 and 12. To confirm the identity of the
sites, this cycle of analysis was repeated on phosphopeptides
recovered from reverse phase HPLC separation after digestion
of PKA/PKG-phosphorylated C130 with V8 endoprotease E
(Fig. 2E). These three peptides were subjected to Edman cy-
cling (Fig. 2 F–H). CRP analysis was then carried out using
cleavage at glutamic acid as the reference point. Cross-refer-
encing CRP analysis at lysine with glutamic acid unambigu-
ously identified Ser-692, Ser-695, and Ser-852 (of the human
isoform, corresponding to Ser-650, Ser-653, and Ser-808 on the
chicken M130 protein) as sites phosphorylated by PKA/PKG on
rMYPT1. Peak I (endoprotease Lys-C) was the peptide contain-
ing the Ser-852 site, and peak II (endoprotease Lys-C) con-
tained Ser-692 and Ser-695. Analysis of a time course of phos-
phorylation of peptide II showed that the phosphorylation of
Ser-692 and Ser-695 was not ordered, i.e. one site does not need
to be phosphorylated before the other one can be. Some phos-
phorylation of threonine in peak 2 (endolysine protease C) and
peak 3 (V8 E) was noted at later time points.
PKA/PKG Phosphorylation of MYPT1 Does Not Affect
SMPP-1M Activity in Vitro—The effect of phosphorylation of
MYPT1 by PKA/PKG on SMPP-1M activity was determined.
Purified full-length rMYPT1 (M110) that had been incubated
with the phosphatase catalytic subunit PP-1C was phosphoryl-
ated by PKG. As a control, parallel reactions using rMYPT1K
were performed. Phosphatase assays were carried out with
32P-labeled smooth muscle myosin as the substrate. Phospho-
rylation of recombinant SMPP-1M by PKG does not affect
phosphatase activity (Fig. 3A). In contrast, phosphorylation of
the enzyme by rMYPT1K dramatically inhibits activity, which
corroborates previous work (8) showing that MYPT1K prefer-
entially phosphorylates Thr-696, inhibiting SMPP-1M activity.
The Phosphorylation Sites for PKA, ROCK, and rMYPT1K
Are Mutually Dependent—Because the in situ data suggested
that pre-phosphorylation of MYPT1 by PKA was affecting cal-
cium sensitization, we investigated the effect of pre-phospho-
rylation of GST-MYPT1 (M133 isoform) by PKA on the ability
of known SMPP-1M inhibitory kinases, ROCK and MYPT1K,
to phosphorylate rMYPT1. Pre-phosphorylation of GST-
MYPT1 (M133) by PKA to 2 mol of phosphate/mol of GST-
MYPT1 caused a dramatic decrease in the subsequent phos-
phorylation of MYPT1 by ROCK and 0.26 mol/mol in contrast
to 1.60 mol/mol phosphorylation of MYPT1 by ROCK without
PKA pre-phosphorylation (Fig. 3, B and C). The reverse reac-
tion also occurs in which pre-phosphorylation of MYPT1 by
ROCK decreased further phosphorylation by PKA (Fig. 3C).
Note that the extent of phosphorylation by PKA in the sample
FIG. 1. In situ treatment of smooth muscle strips with 8-bromo-
cGMP reduces the calcium sensitization effect of exogenous
MYPT-1 kinase (MYPT1K). A and B, longitudinal -escin-permeabi-
lized ileum smooth muscle strips (200 m [times] 4 mm) were isolated
and placed in an intracellular solution containing 1 mM EGTA (G1), 10
mM EGTA (G10), or 30 M Ca2 (CaG). Strips were treated with vehicle
(A) or 100 M 8-bromo-cGMP (B) for 5 min and then contracted with 10
M MYPT1K. C, pretreatment with 8-bromo-cGMP reduced the maxi-
mum contraction elicited by addition of MYPT1K. * indicates signifi-
cance at p  0.04.
Cyclic Nucleotide Regulation of MYPT1 Phosphorylation34498
 by guest, on January 12, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
pre-phosphorylated by ROCK is about 0.95 mol of phosphate/
mol (over a 150-min incubation) compared with about 2.2 mol of
phosphate/mol (over a similar time period) with PKA alone
(Fig. 3B). Similar experiments were carried out with PKA and
rMYPT1K. Pre-phosphorylation of GST-MYPT1K by PKA re-
duced subsequent phosphorylation by rMYPT1K to about 0.4
mol phosphate/mol (Fig. 3D). By using the opposite sequence,
pre-phosphorylation by rMYPT1K (to about 1.7 mol of phos-
phate/mol) attenuated phosphorylation by PKA (increase of
only 0.25 mol of phosphate/mol) and essentially blocked phos-
phorylation by ROCK (Fig. 3E). These data suggest that the
adjacent phosphorylation sites on MYPT1 for PKA, ROCK, and
rMYPT1K are dependent on phosphorylation of the partner
site. Although the emphasis in this article is on the pair of sites
containing the inhibitory site (i.e. Ser-695 and Thr-696), it is
evident that the adjacent sites containing the second major
ROCK site (i.e. Ser-852 and Thr-853) may be subject to the
same mutual dependence.
Another approach to assess the influence of the adjacent
Ser-695 and Thr-696 sites was to use the synthetic substrate
peptide (residues 689–700). Because Ser-691 (avian number-
ing) was identified as a PKA/PKG site, the Ser-691 to Ala
mutant was used (see ‘‘Experimental Procedures’’) to simplify
analysis. Both PKA and MYPT1K readily phosphorylated the
peptide to 1 mol/mol. Phosphorylation site analysis using ra-
dioactivity release during Edman sequence analysis confirmed
FIG. 2. Identification of in vitro PKA/PKG phosphorylation sites on recombinant MYPT1 (C130). A, inset, C130 was phosphorylated by
PKG (shown) and PKA. The stoichiometry of phosphorylation was 3.5 mol of phosphate/mol of C130. A, three phosphopeptides were isolated from
PKG-phosphorylated C130 on reverse phase HPLC following digestion with endoproteinase Lys-C. B–D, the PKG phosphorylation sites on
32P-labeled C130 were identified by differential protease treatment followed by Edman sequencing with 32P-release. Precise sites were identified
using the CRP method. E, PKG-phosphorylated MYPT1 was cleaved with V8 endoproteinase E, and three peaks of radioactivity were identified.
F–H, Edman cycle analysis was repeated by using cleavage at glutamic acid as the reference point to identify precisely the sites identified with
endoproteinase Lys-C cleavage. Cross-referencing CRP analysis at lysine with glutamic acid identified Ser-692, Ser-695, and Ser-852 (human
numbering) as the sites phosphorylated by PKA/PKG on MYPT1.
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that PKA phosphorylated Ser-695, whereas rMYPT1K phos-
phorylated Thr-696. To test the ability of Ser-695 phosphoryl-
ation to interfere with phosphorylation of Thr-696, the peptide
was pre-phosphorylated in the presence and absence of PKA by
using nonradioactive ATP. After 30 min, rMYPT1K was added
with [-32P]ATP, and the reaction was followed over the indi-
cated times (Fig. 3F). Phosphorylation of Thr-696 by rMYPT1K
was considerably reduced after pre-phosphorylation of Ser-695.
The rate of phosphorylation of the peptide without PKA pre-
treatment was 3.8 nmol of Pi/min versus 1.5 nmol of Pi/min
with PKA pre-phosphorylation (Fig. 3F). Phosphoamino acid
analysis confirmed a significant reduction in phosphothreonine
content in the PKA-treated peptide compared with non-PKA-
treated peptide (Fig. 3G). The reverse sequence, i.e. rMYPT1K
followed by PKA, also blocked the ability of PKA to phospho-
rylate the substrate peptide at Ser-695 (data not shown).
In the final in vitro experiment, GST-MYPT1 (M133 isoform)
was thiophosphorylated with PKA, dialyzed, and then sub-
jected to phosphorylation by ROCK. (Further prolonged phos-
phorylation by PKA and [-32P]ATP resulted only in the incor-
poration of 0.11 mol of phosphate/mol, suggesting saturation by
thiophosphorylation.) Phosphorylation of non-thiophosphoryl-
ated GST-MYPT1 by ROCK resulted in the incorporation of 1.9
mol of phosphate/mol, but in the thiophosphorylated sample
only 0.4 mol of phosphate/mol was incorporated (Fig. 4A).
These data again suggested that both pairs of sites (Ser-695/
Thr-696 and Ser-852/Thr853) were influenced. Western blots
carried out over the reaction time course (with the pMYPT1T696
antibody) indicated a reduced level of phosphorylated Thr-696
in the thiophosphorylated sample (Fig. 4B). Phosphatase as-
says were carried out (using 32P-labeled MLC-20) to determine
the extent of inhibition of PP1c by the two GST-MYPT1 sam-
ples (i.e. aliquots were removed at the end of the reaction
shown in Fig. 4A). The IC50 for GST-MYPT1 phosphorylated
only by ROCK was about 0.25 nM compared with about 2.4 nM
for the PKA/ROCK sample (Fig. 4C). These data indicate the
reduced level of phosphorylated Thr-696 in the sample thio-
phosphorylated with PKA.
Overall, the in vitro data are consistent with a potential
regulatory mechanism, in which phosphorylation of Ser-695 by
PKA/PKG could influence SMPP-1M activity by reducing phos-
phorylation of the inhibitory site by rMYPT1K or other kinases.
In effect, the phosphorylation by PKA would extend a more
active state for SMPP-1M.
FIG. 3. PKG/PKA phosphorylation does not affect SMPP-1M activity in vitro, pre-phosphorylation of MYPT1 by PKA decreases
phosphorylation of MYPT1 by ROCK and MYPT1K in vitro, and the phosphorylation of Ser-695 and Thr-696 is mutually exclusive
in vitro. A, full-length recombinant MYPT1 was thiophosphorylated by PKG (and PKA, not shown) or MYPT1K prior to performing SMPP-1M
phosphatase activity assays. B, phosphorylation of MYPT1 first by PKA and then by ROCK. 2 M GST-MYPT1 was phosphorylated by PKA (1
g/ml), and aliquots taken at indicated time intervals were assayed for 32P incorporation (). After 150 min, part of the reaction mixture was
removed, and the phosphorylation reaction continued in the presence of ROCK (0.4 units/ml) up to 300 min (E). C, phosphorylation of 2 M
GST-MYPT1 first by ROCK (‚) and then by PKA (). D, phosphorylation of GST-MYPT1 first by PKA () and then by MYPT1K (44 g/ml) (E).
E, phosphorylation of GST-MYPT1 first by MYPT1K (E) and then by PKA () or ROCK (‚). F, phosphorylation at Ser-695 by PKG/PKA precludes
Thr-696 phosphorylation by MYPT-1 kinase. A peptide, 689RQARRSTQGVTL700 (avian numbering), encoding the inhibitory phosphorylation region
of MYPT1 with a Ser to Ala exchange at 691, was phosphorylated to 0.8 mol/mol with PKA and nonradioactive ATP. This phosphorylation
substantially reduced the subsequent rate of phosphorylation by MYPT1K. The rates of phosphorylation with and without PKA treatment are
indicated. G, phosphoamino acid analysis confirmed that increased Ser-695 phosphorylation by PKA reduced the Thr-696 phosphorylation by
MYPT1K.
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Ser-695 Is Phosphorylated in Smooth Muscle in Response to
8-Bromo-cGMP, and Phosphorylation of This Site Blocks Phos-
phorylation of Thr-696—To determine whether SMPP-1M is
regulated by a mutual exclusion mechanism involving phos-
phorylation of Ser-695 under in vivo conditions in smooth mus-
cle, it was necessary to generate a phosphospecific antibody to
this site. This was raised in rabbits using the synthetic phos-
phopeptide 689RQSRRpSTQGVTL700 as the antigen. The anti-
body was affinity-purified over a 689RQSRRpSTQGVTL700 pep-
tide affinity column. To determine the selectivity and
sensitivity of the antibody, recombinant MYPT1 was phospho-
rylated to completion with MYPT1K (2 mol/mol) and PKA
(2.5–3 mol/mol). Radioactive release by Edman sequencing was
used to confirm that Thr-696 and Ser-695 were phosphoryl-
ated, respectively. The phosphoproteins were diluted and
tested against the pMYPT1S695 antibody. Fig. 5A shows that
the pMYPT1S695 antibody has a high degree of selectivity to-
ward phosphorylated Ser-695 over phosphorylated Thr-696 at
a 1/10,000-fold dilution (or 0.1 g of antibody/ml). The figure
shows that at the highest concentration of MYPT1 tested (3
g), the pMYPT1S695 antibody shows an 100-fold selectivity
toward pMYPT1S695 over pMYPT1T696. At0.75 g of MYPT1,
no cross-reactivity with pMYPT1T696 was detected. A time
course study shows the sensitivity and selectivity of the
pMYPT1S695 antibody toward Ser-695 over Thr-696 at 3 g of
MYPT1 (Fig. 5B). A commercial pMYPT1T696 antibody recog-
nizes Thr-696 phosphorylation by MYPT1K and ROCK, and
there is slight recognition of PKA phosphorylated MYPT1 by
this antibody (Fig. 5C). The pMYPT1S695 antibody only recog-
nized PKA-phosphorylated MYPT1.
By having demonstrated the selectivity of the pMYPT1S695
antibody in vitro, we used the antibody to examine the phos-
phorylation state of Ser-695 in smooth muscle. For the ileal
smooth muscle experiments, squares of muscle (5 mg w/w) were
permeabilized in silicone dishes with -escin (5). The intracel-
lular concentration of MYPT1 in smooth muscle has been de-
termined to be between 0.8 and 2 M (19). By assuming an
intracellular space of 30% (w/w), the estimated amount of
MYPT1 in smooth muscle is 62–154 ng/mg (w/w.). Based on
these calculations, 5 mg of smooth muscle provided sufficient
levels of MYPT1 to measure the phosphorylation state of Ser-
695 at stoichiometries of phosphorylation 0.1 mol/mol. After
maximum Ca2 contraction, the muscles were washed exten-
sively in G10 and treated for 10 min with 100 M 8-bromo-
cGMP or vehicle. The muscles were flash-frozen in liquid N2-
cooled Freon, and extracts were prepared for Western blot
analysis with the pMYPT1S695 antibody. Ser-695 is basally
phosphorylated in smooth muscle at varying levels, and treat-
ment with 8-bromo-cGMP significantly (n  38, p  0.01)
increases the Ser-695 phosphorylation state (Fig. 6, A and C).
To determine directly the effects of phosphorylation of Ser-695
and Thr-696 in smooth muscle, squares of ileum were perme-
abilized with -escin and treated with either vehicle (water) or
FIG. 4. Pre-phosphorylation with PKA reduces Thr-696 phos-
phorylation by ROCK in vitro and increases the IC50 for ROCK
inhibition of SMPP-1M activity. A, GST-MYPT (2 M) was thiophos-
phorylated by PKA for 150 min in the presence of 0.5 mM ATPS and 5
mM Mg2. Thiophosphorylated GST-MYPT1 was then phosphorylated
by ROCK (0.4 units/ml) in the presence of [32P]ATP for 150 min () and
compared with phosphate incorporation of GST-MYTP1 phosphorylated
by ROCK alone (‚). B, aliquots of GST-MYPT1 thiophosphorylated by
PKA or GST-MYPT1 phosphorylated by ROCK alone were taken at the
indicated time points and immunoblotted with pMYPT1T696 antibody.
C, inhibition of PP-1c by GST-MYPT1 phosphorylated by ROCK alone
(‚) or with thiophosphorylation by PKA (). The IC50 for ROCK alone
was 0.25 nM compared with 2.4 nM with PKA thiophosphorylation. The
phosphatase activity in the absence of phospho-MYPT1 was taken as
100%.
FIG. 5. Characterization of a polyclonal phosphospecific anti-
body directed against Ser-695 of MYPT-1. A, decreasing amounts of
MYPT1 (3000 to 1.5 ng) phosphorylated with MYPT1K or PKA were
blotted for pMYPT1S695. B, 3 g of MYPT1 was phosphorylated with
MYPT1K or PKA, and the reaction was stopped at the indicated time
points and immunoblotted using the pMYPT1S695 antibody. C, MYPT1
was phosphorylated with MYPT1K, Rho kinase, PKA, or vehicle control
and blotted with pMYPT1S695 antibody, pMYPT1T696 antibody, or anti-
body against total MYPT1.
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8-bromo-cGMP for 5 min, followed by rMYPT1K for 10 min.
Muscles were flash-frozen in liquid N2-cooled Freon, and ex-
tracts were blotted for phosphorylation of Thr-696 and total
MYPT1. Pretreatment of muscles with 8-bromo-cGMP signifi-
cantly (n  17, p  0.04) reduced Thr-696 phosphorylation as
compared with vehicle-treated tissues (Fig. 6, B and D). The
finding that phosphorylation of Ser-695 reduces phosphoryla-
tion of Thr-696 by MYPT1K explains the attenuation of force
development shown in Fig. 1 following addition of the kinase to
8-bromo-cGMP-treated muscles.
DISCUSSION
The results obtained in this work show that Ser-695 on
MYPT1 is phosphorylated in smooth muscle in response to
cGMP activation, and phosphorylation of this site reduces sub-
sequent phosphorylation of Thr-696. These findings suggest a
possible mechanism of Ca2 desensitization involving mutual
exclusion of phosphorylation. Activation of PKG/PKA leads to
phosphorylation of MYPT1, which prevents phosphorylation of
Thr-696 by MYPT1K and likely ROCK, thereby blocking inac-
tivation of SMPP-1M (Fig. 7A). Such a mechanism of regulation
is consistent with the fine level of control of contraction that is
required of smooth muscle under normal physiological
conditions.
The contractile state of any smooth muscle is governed by the
balance of opposing activities of MLCK and SMPP-1M, which
controls the steady state phosphorylation of MLC-20. Activa-
tion or inhibition of either the kinase or phosphatase results in
profound effects on the level of phosphorylation of MLC-20 and,
therefore, the contractile state of the muscle. Regulation of
SMPP-1M through phosphorylation of MYPT1 has been estab-
lished as a primary mechanism by which the contractile state
can be controlled independently of [Ca2]. Several protein ki-
nases that specifically target Thr-696 have been identified in
addition to MYPT1K, including ROCK, myotonic dystrophy
kinase, and integrin-linked protein kinase (5, 6, 8–10). Phos-
phorylation of Thr-696 by these kinases in smooth muscle has
been shown to inhibit SMPP-1M and cause Ca2 sensitization
(4–6, 9, 10, 23). Ca2 sensitization/desensitization pathways
are essential for maintenance of normal smooth muscle tone,
and abnormalities in these pathways have been shown to be
key components in the pathogenesis of diseases such as hyper-
tension and asthma (3, 4, 24). Signaling through G protein-
coupled Ca2 sensitization pathways has been shown to be
FIG. 7. A, PKA/PKG phosphorylation sites identified on MYPT1 in
vitro. Ser-692 and Ser-695 were found in peptide II, and phosphoryla-
tion of Ser-695 was found to inhibit phosphorylation of the adjacent
Thr-696 MYPT1K/ROK inhibitory site. Ser-852 was also identified as a
PKA/PKG phosphorylation site in peptide I and may lead to inhibition
of phosphorylation of the adjacent Thr-853 site. LZ, leucine zipper. B,
proposed mechanism for calcium desensitization induced by cyclic nu-
cleotide kinases in smooth muscle. Calcium-independent contraction
elicited by kinases such as ROCK or MYPT1K is caused by inhibition of
myosin phosphatase activity by phosphorylation of Thr-696 on MYPT1.
Phosphorylation of Thr-696 is inhibited by Ser-695 phosphorylation by
PKA/PKG, thus effectively leading to indirect activation of SMPP-1M
activity by cyclic nucleotide kinases.
FIG. 6. Ser-695 phosphorylation of native MYPT1 is increased by cGMP stimulation, and phosphorylation of this site blocks
phosphorylation of Thr-696. A, permeabilized rabbit ileum was stimulated with 100 M 8-bromo-cGMP (cG) or vehicle (veh) for 10 min and
immunoblotted with the pMYPT1S695 antibody or antibody against total MYPT1. Representative Western blot results of multiple experiments are
shown. B, permeabilized rabbit ileum was stimulated with 100 M 8-bromo-cGMP (cG) or vehicle (veh) for 5 min and then treated with 10 M
MYPT1K and immunoblotted with the pMYPT1T696 antibody or antibody against total MYPT1. C, summarized data of densitometric analyses of
Ser-695 phosphorylation in permeabilized ileum. Control, ileum without stimulation; cG, ileum stimulated for 10 min with 100 M 8-bromo-cGMP.
(* indicates significance at p  0.01.) D, summarized data of densitometric analysis of Thr-696 phosphorylation in permeabilized ileum. Con-
trol  MYPT1K, no stimulation before MYPT1K administration; cG  MYPT1K, 100 M 8-bromo-cGMP administered before MYPT1K for 5 min.
(* indicates significance at p  0.04.) Mean density of phosphorylated MYPT1 versus the total MYPT1 density for the controls was expressed
as 1 arbitrary unit.
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up-regulated in multiple models of hypertension, cerebral va-
sospasm, bronchial asthma, and erectile dysfunction, and RhoA
or ROCK inhibitors can be effective for treatment of these
conditions (3, 24–28).
We have shown herein that 8-bromo-cGMP greatly attenu-
ates the Ca2-sensitizing actions of MYPT1K, demonstrating
the capacity for PKG to regulate SMPP-1M in smooth muscle.
Although MYPT1 is clearly phosphorylated by PKA/PKG in
smooth muscle, this does not affect SMPP-1M activity directly.
The question then arises, how can activation of PKG/PKA
affect contractile activity through altering SMPP-1M activity?
In vitro data showed that phosphorylation of recombinant full-
length MYPT1 by PKA reduced subsequent phosphorylation by
ROCK and MYPT1K. The reverse situation also occurred. In
vitro data also showed that thiophosphorylation of MYPT1 by
PKA reduced the ability of ROCK to inhibit phosphatase activ-
ity, supporting an indirect mechanism of phosphatase activa-
tion. We found three PKA/PKG phosphorylation sites on
MYPT1 (Ser-692, Ser-695, and Ser-852) (Fig. 7A). We chose to
pursue Ser-695 because this site was adjacent to the inhibitory
Thr-696 site. Our hypothesis was that phosphorylation at this
site could affect SMPP-1M activity indirectly through mutual
exclusion of phosphorylation. A similar mechanism could apply
to Ser-852 and Ser-853, but that was not pursued in this study.
The level of reduction in phosphorylation observed in vitro on
full-length recombinant MYPT1 suggested that both the inhib-
itory Thr-696 and the Th-r853 sites on MYPT1 might be af-
fected by mutual exclusion of phosphorylation. In vitro data
using synthetic peptides and phosphoamino acid analysis also
showed that PKA phosphorylation reduces the rate of MYPT1
phosphorylation by MYPT1K, and Thr-696 phosphorylation is
reduced dramatically as Ser-695 phosphorylation increases.
Regulation of enzyme activity by mutual exclusion of phos-
phorylation is well described. Examples of this mechanism of
regulation occur with both hormone-sensitive lipase and 3-hy-
droxy-3-methylglutaryl-CoA reductase (29–31). Based on our
data, we suggest that phosphorylation of Ser-695 in response to
cGMP/cAMP alters the balance of SMPP-1M activity through
competition with opposing RhoA-mediated Ca2-sensitizing
pathways acting through MYPT1K or ROCK (or other kinases).
In the mechanism outlined in Fig. 7B, the balance of Ser-695
and Thr-696 phosphorylation acts as a homeostatic system to
check the impact of opposing Ca2-desensitizing/sensitizing
pathways. Such a mechanism provides exquisite control of the
smooth muscle contractile state, allowing muscles to respond in
a highly coordinate fashion to a given physiological situation. If
this mechanism is accepted then a critical corollary is the role
of the phosphatase(s) involved in dephosphorylation of the var-
ious sites. Obviously, the lifetime of any blocking effect would
reflect the activity of the phosphatase involved. Intuitively, it
might be predicted that the activity of the phosphatase for
Ser(P)-695 (or Ser(P)-852) would differ from that for Thr(P)-696
(or Thr(P)-853). Equal phosphatase activity for Ser(P)-695 and
Thr(P)-696 seems to be counter productive.
We noted some Ser-695 phosphorylation in control tissues. In
the permeabilized ileum smooth muscle, some of this could
have been due to inconsistencies in stretch of the muscle. There
is also likely a basal level of phosphorylation, which further
supports the idea that Ca2 desensitization is not necessarily
an ‘‘on or off’’ mechanism of smooth muscle regulation, rather a
method of making fine adjustments to various physiologic con-
ditions, which can lead to pathologic conditions if the system
goes awry (3, 4, 24).
Several mechanisms probably are involved in the Ca2 de-
sensitization of smooth muscle induced by an increase in
cAMP/cGMP concentrations. Our results suggest one possibil-
ity, but other mechanisms should be considered. Perhaps most
interesting in light of the above data is the suggestion that
phosphorylation of Thr-853 (i.e. the second major site for
ROCK) of MYPT1 reduces binding to myosin leading to de-
creased SMPP-1M activity (32). The in vitro evidence, pre-
sented above, suggests that both ROCK sites would be blocked
by phosphorylation of adjacent PKA sites. Another mechanism
may involve different cellular locations of MYPT1, depending
on its state of phosphorylation (15, 16). With respect to other
proteins, additional targets for PKG/PKA in smooth muscle
include Hsp20 and telokin (33). In the case of telokin the in
vitro PKG/PKA sites have been identified, and phosphorylation
promotes Ca2 desensitization in permeabilized smooth muscle
(34–37). Thus it is possible that phosphorylation of Ser-695
acts in collaboration with other mechanisms to promote the
relaxation of smooth muscle. The combination of different
PKG/PKA targets may provide an attractive explanation un-
derlying the varied contractile responses in different smooth
muscles.
In summary, we identified three PKA/PKG phosphorylation
sites on MYPT1. Phosphorylation has no direct effect on
SMPP-1M activity, so we pursued the Ser-695 phosphorylation
site as a potential mechanism of SMPP-1M activation through
mutual exclusion of phosphorylation. This work shows that
Ser-695 on MYPT1 is phosphorylated in smooth muscle in
response to 8-bromo-cGMP, and phosphorylation of this site
prevents phosphorylation of the inhibitory site Thr-696. Our
proposed mechanism of Ca2 desensitization is activation of
PKG/PKA, leading to phosphorylation of Ser-695 of MYPT1,
which prevents phosphorylation of Thr-696 by MYPT1K and
likely RhoA-activated kinases, thereby blocking inactivation of
SMPP-1M. This mechanism of Ca2 desensitization is a poten-
tial mechanism of fine control over smooth muscle tone, which
is essential for maintenance of normal physiology.
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